Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression
Taylor Lyons, Robin Carhart-Harris
Journal of Psychopharmacology January 17, 2018 DOI: 10.1177/0269881117748902 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label pilot study with mixed-model design Peer reviewed |
|---|---|
| Sample size | 14 |
| Population | Patients with moderate to severe treatment-resistant depression (n=7) and age-matched healthy control subjects (n=7) |
| Intervention | Psilocybin |
| Dose | 10 mg and 25 mg |
| Duration | Two dosing sessions 1 week apart, with follow-up at 1 week and 7–12 months after the second session |
| Topics | Psilocybin Depression |
| Keywords | Authoritarianism Dosing Depression economics Clinical psychology Politics Hallucinogen |
| Citations | 176 |
| Key points | Psilocybin increased nature relatedness and decreased authoritarianism in patients with treatment-resistant depression, with the increase in nature relatedness persisting for 7–12 months. |
Abstract
Rationale: Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations.
Aim: Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian–authoritarian political perspective in patients with treatment-resistant depression (TRD).
Methods: This open-label pilot study with a mixed-model design studied the effects of psilocybin on measures of nature relatedness and libertarian–authoritarian political perspective in patients with moderate to severe TRD ( n=7) versus age-matched non-treated healthy control subjects ( n=7). Psilocybin was administered in two oral dosing sessions (10 mg and 25 mg) 1 week apart. Main outcome measures were collected 1 week and 7–12 months after the second dosing session. Nature relatedness and libertarian–authoritarian political perspective were assessed using the Nature Relatedness Scale (NR-6) and Political Perspective Questionnaire (PPQ-5), respectively.
Results: Nature relatedness significantly increased ( t(6)=−4.242, p=0.003) and authoritarianism significantly decreased ( t(6)=2.120, p=0.039) for the patients 1 week after the dosing sessions. At 7–12 months post-dosing, nature relatedness remained significantly increased ( t(5)=−2.707, p=0.021) and authoritarianism remained decreased at trend level ( t(5)=−1.811, p=0.065). No differences were found on either measure for the non-treated healthy control subjects.
Conclusions: This pilot study suggests that psilocybin with psychological support might produce lasting changes in attitudes and beliefs. Although it would be premature to infer causality from this small study, the possibility of drug-induced changes in belief systems seems sufficiently intriguing and timely to deserve further investigation.
Comparable studies
Other non-randomized and open-label trials on psilocybin for depression, most cited first.
Citations in the library
Cited by 120
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Effects of psilocybin therapy on personality structure Acta Psychiatrica Scandinavica June 19, 2018
- Long-term effects of psychedelic drugs: A systematic review Neuroscience & Biobehavioral Reviews March 16, 2020
- The Therapeutic Potential of Psilocybin Molecules May 15, 2021
- DMT Models the Near-Death Experience Frontiers in Psychology August 15, 2018
and 115 more in the library
Cites 35
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
and 30 more in the library